Class III antiarrhythmic agents in cardiac failure: Lessons from clinical trials with a focus on the grupo de estudio de la sobrevida en la insuficiencia cardiaca en Argentina (GESICA)

American Journal of Cardiology

Volumn 84, Issue 9 SUPPL. 1, 1999, Pages 109-114

  Doval, Hernan C ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOFETILIDE; PLACEBO; SOTALOL; SPIRONOLACTONE;

CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTHYROIDISM; IMPLANT; META ANALYSIS; MORTALITY; PRIORITY JOURNAL;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 0032745007     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00711-0     Document Type: Conference Paper

References (30)

1. Garg R.G., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 273:1995;1450-1456.
2. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
3. Cleland J.G.F., Bristow M.R., Eerdmann E., Remme W.J., Swedberg K., Waagstein F. Beta-blocking agents in heart failure Should they be used and how? Eur Heart J. 17:1996;1629-1639.
4. Singh B.N. Current antiarrhythmic drugs an overview of mechanisms of action and potential clinical utility . J Cardiovasc Electrophysiol. 10:1999;283-301.
5. Zivin A., Bardy G.H. Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias a critical perspective . Am J Cardiol. 84:1999;63R-68R.
6. Stevenson W.G., Stevenson L.W., Middlekauff H.R., Fonarow G.C., Hamilton M.A., Woo M.A., Saxon L.A., Natterson P.D., Steimle A., Walden J.A., et al. Improving survival for patients with advanced heart failure a study of 737 consecutive patients . J Am Coll Cardiol. 26:1995;1417-1423.
7. Teo K.K., Yusuf S., Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction an overview of results of randomized controlled clinical trials . JAMA. 270:1993;1589-1595.
8. Waldo A.L., Camm A.J., de Ruyter H., Friedman P.L., MacNeil D.J., Pauls J.F., Pitt B., Pratt C.M., Schwartz P.J., Veltri E.P. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral D-Sotalol. Lancet. 348:1996;7-12.
9. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction rationale, design, and patient characteristics of the DIAMOND studies . Clin Cardiol. 20:1997;704-710.
10. Doval H.C., Nul D.R., Grancelli H.O., Perrone S.V., Bortman G.R., Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 344:1994;493-498.
11. Singh S.N., Fletcher R.D., Fisher S.G., Singh B.N., Lewis H.D., Deedwania P.C., Massie B.M., Colling C., Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 333:1995;77-82.
12. Garguichevich J.J., Ramos J.L., Gambarte A., Gentile A., Hauad S., Scapin O., Sirena J., Tibaldi M., Toplikar J. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias Argentine pilot study of sudden death and amiodarone (EPAMSA) . Am Heart J. 130:1995;494-500.
13. Nicklas J.M., McKenna W.J., Stewart R.A., Mickelson J.K., Das S.K., Schork M.A., Krikler S.J., Quain L.A., Morady F., Pitt B. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J. 122:1991;1016-1021.
14. Hamer A.W.F., Arkles L.B., Johns J.A. Beneficial effects of low dose amiodarone in patients with heart failure a placebo-controlled trial . Am J Cardiol. 14:1989;1768-1773.
15. Pratt C.M., Camm A.J., Cooper W., Friedman P.L., MacNeil D., Moulton F.M., Putt B., Schwartz P.J., Veltri E.P., Waldo A.L. Mortality in the Survival With ORal D-sotalol (SWORD) trial Why did patients die? Am J Cardiol. 81:1998;869-876.
16. Kaber L. Dofetilide, a new class III antiarrhythmic drug reduces hospital admissions for congestive heart failure - secondary endpoints of the DIAMOND-CHF study. (Abstr.) J Am Coll Cardiol. 31:(suppl A):1998;33A.
17. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure meta-analysis of individual data from 6500 patients in randomised trials . Lancet. 350:1997;1417-1424.
18. Singh S.N., Fisher S.G., Carson P.E., Fletcher R.D. Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. J Am Coll Cardiol. 32:1998;942-947.
19. Massie B.M., Fisher S.G., Radford M., Deedwania P.C., Singh B.N., Fletcher R.D., Singh S.N. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation. 93:1996;2128-2134.
20. Nul D.R., Doval H.C., Grancelli H.O., Varini S.D., Soifer S., Perrone S.V., Prieto N., Scapin O. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. J Am Coll Cardiol. 29:1997;1199-1205.
21. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction EMIAT . Lancet. 349:1997;667-673.
22. Cairns J.A., Connolly S.J., Roberts R.J., Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations CAMIAT . Lancet. 394:1997;675-682.
23. Boutitie F., Boissel J.P., Connolly S.J., Camm A.J., Cairns J.A., Julian D.G., Gent M., Janse M.J., Dorian P., Frangin G. Amiodarone Interaction with β-Blockers analysis of the merged EMIAT and CAMIAT databases . Circulation. 99:1999;2268-2275.
24. Packer M., Colucci W.S., Sackner-Bernstein J.D., Liang C.S., Goldscher D.A., Freeman I., Kukin M.L., Kinhal V., Udelson J.E., Klapholz M., Gottlieb S.S., Pearle D., Cody R.J., Gregory J.J., Kantrowitz N.E., LeJemtel T.H., Young S.T., Lukas M.A., Shusterman N.H. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure the Precise Trial . Circulation. 94:1996;2793-2801.
25. Packer M., Bristow M.R., Cohn J.N. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
26. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) . Lancet. 353:1999;2001-2007.
27. The cardiac insufficiency bisoprolol study II (CIBIS II). Lancet. 353:1999;9-13.
28. Ogunyankin K., Singh B.N. Mortality reduction by antiadrenergic modulation of arrythmogenic substrate signficance of combining beta-blockers and amiodarone . Am J Cardiol. 84:1999;76R-82R.
29. Massie B.M., Cleland J.B., Armstrong P.W., Horowitz J.D., Packer M., Poole-Wilson P.A., Ryden L. Regional differences in the characteristics and treatment of patients in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. J Cardiac Fail. 4:1998;3-8.
30. Bardy G, Lee K , Mark D, Poole J, Fishbein D, Singh S, Troutman C, Christian V, Anderson J, Capp-Channing, Johnson G, for the SCD-HeFT Investigators. SCD-HeFT: prevention of Sudden Cardiac Death in patients with congestive Heart Failure Trial. In : Woosley R, Singh S, eds. Clinical Trials in Arrhythmias. 1999, Marcel Decker, in press.